These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34228837)

  • 21. [Effects of angiotensin II type 1 receptor blocker on islet of diabetic db/db mice].
    Shao JQ; Iwashita N; Du H; Wang YY; Zhao M; Wang J; Watada H; Kawamori R
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):306-10. PubMed ID: 17637271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Positive effects of angiotensin [corrected] receptor blockers on the course of microvascular complications of diabetes mellitus].
    Tsutskiridze LR; Kurashvili RB; Tsibadze AD; Kurashvili GR; Shelestova EL
    Georgian Med News; 2008 Sep; (162):54-7. PubMed ID: 18830032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment.
    Fujita A; Yoh K; Shimohata H; Morito N; Ojima M; Okamura M; Takahashi S; Yamagata K
    Exp Anim; 2012; 61(1):49-57. PubMed ID: 22293672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
    Haneda M; Kikkawa R; Sakai H; Kawamori R;
    Diabetes Res Clin Pract; 2004 Oct; 66(1):87-95. PubMed ID: 15364166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.
    Andersen S; Mischak H; Zürbig P; Parving HH; Rossing P
    BMC Nephrol; 2010 Nov; 11():29. PubMed ID: 21040538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.
    McMullan CJ; Lambers Heerspink HJ; Parving HH; Dwyer JP; Forman JP; de Zeeuw D
    Am J Kidney Dis; 2014 Nov; 64(5):714-22. PubMed ID: 25064674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of angiotensin type-1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus.
    Malik RA; Schofield IJ; Izzard A; Austin C; Bermann G; Heagerty AM
    Hypertension; 2005 Feb; 45(2):264-9. PubMed ID: 15630048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Abnormal Renal Profiles and Proliferative Diabetic Retinopathy and Diabetic Macular Edema in an Asian Population With Type 2 Diabetes.
    Hsieh YT; Tsai MJ; Tu ST; Hsieh MC
    JAMA Ophthalmol; 2018 Jan; 136(1):68-74. PubMed ID: 29167896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
    Porta M; Hainer JW; Jansson SO; Malm A; Bilous R; Chaturvedi N; Fuller JH; Klein R; Orchard T; Parving HH; Sjølie AK;
    Diabetologia; 2011 Jun; 54(6):1298-303. PubMed ID: 21225239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns.
    Rossing K; Mischak H; Parving HH; Christensen PK; Walden M; Hillmann M; Kaiser T
    Kidney Int; 2005 Jul; 68(1):193-205. PubMed ID: 15954909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design.
    Chaturvedi N; Sjoelie AK; Svensson A;
    J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):255-61. PubMed ID: 12584669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
    Ketelhut R; Bramlage P
    Clin Drug Investig; 2010; 30(5):301-11. PubMed ID: 20384386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diabetic retinopathy candesartan trial].
    Morise A; Sakamoto K; Shiba T
    Nihon Rinsho; 2010 Nov; 68 Suppl 9():276-84. PubMed ID: 21661164
    [No Abstract]   [Full Text] [Related]  

  • 34. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
    Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
    Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].
    MMW Fortschr Med; 2004 Jan; 146(5):47. PubMed ID: 15035422
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
    Estacio RO; Coll JR; Tran ZV; Schrier RW
    Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes.
    Sugiyama T; Okuno T; Fukuhara M; Oku H; Ikeda T; Obayashi H; Ohta M; Fukui M; Hasegawa G; Nakamura N
    Exp Eye Res; 2007 Sep; 85(3):406-12. PubMed ID: 17678894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
    Riphagen IJ; Deetman PE; Bakker SJ; Navis G; Cooper ME; Lewis JB; de Zeeuw D; Lambers Heerspink HJ
    Diabetes; 2014 Aug; 63(8):2845-53. PubMed ID: 24677717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.
    Heck SL; Mecinaj A; Ree AH; Hoffmann P; Schulz-Menger J; Fagerland MW; Gravdehaug B; Røsjø H; Steine K; Geisler J; Gulati G; Omland T
    Circulation; 2021 Jun; 143(25):2431-2440. PubMed ID: 33993702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials.
    Féghali RE; Nisse-Durgeat S; Asmar R
    Vasc Health Risk Manag; 2007; 3(1):165-71. PubMed ID: 17583187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.